Topics

Companies Related to "Cerevance Achieves Endpoints Phase Clinical Trial Novel Parkinson" [Most Relevant Company Matches] RSS

20:44 EDT 15th September 2019 | BioPortfolio

Here are the most relevant search results for "Cerevance Achieves Endpoints Phase Clinical Trial Novel Parkinson" found in our extensive corporate database of over 50,000 company records.

Showing "Cerevance Achieves Endpoints Phase Clinical Trial Novel Parkinson" Companies 1–25 of 5,700+

Extremely Relevant

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...


Quantum Clinical Research

Global Clinical Trial/Project Management Therapeutic Specialization Phase I Clinical Trial Mgmt Capabilities Phase II-III Capabilities Phase IIIb –IV Capabilities Post marketing Surveillance Treatment IND & Compassionate Use Regulatory Operations & QA Capabilities Worldwide Drug Safety Clinical Trial Monitoring CRA/Monitor Training Select Biometrics Capabilities

Cerevance

Cerevance is a recently formed pharmaceutical company focused on central nervous system diseases. The company’s strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. Its scientists believe that they are well positioned to deliver life-changing therapeutics for ...


Relevant

Intec Pharma Ltd.

Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and s...

Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical tri...

CRDE Sp. j.

CRDE was founded in 2002 as niche CRO focused on managing clinical trials phase I-IV in oncology, metabolic disorders, cardiovascular disorders and pediatrics. Such therapeutic areas are very demanding and require specialized knowledge to understand study design and procedures, endpoints, safety issues and patient populationsOur Medical and Clinical Operations staff have proven experience and appl...

FaustPharmaceuticals

Created in October 2001, FaustPharmaceuticals is a spin-off of the Centre National de Recherche Scientifique (CNRS), based on technologies developed by Dr. Maurice Israel. In November 2003, FaustPharmaceuticals acquired Euroclide.Up to date, FaustPharmaceuticals has raised M€ 19 in two series of fund raising (M€ 3 in Feb. 2002, M€ 16 in Apr. 2004).After a first year of incubation in the labo...

Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is focusing on development ...

ADA Medical Ltd.

ADA Medical Ltd. is a Research Partnership Group of research professionals dedicated to the successful implementation and completion of clinical research projects for the pharmaceutical, biotechnology and medical device industries. We specialize in trial management and support for hospital based as well as outpatient Phase IIb through Phase IV clinical tri...

Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule drugs for the treatment of central nervous system (CNS) diseases. Our clinical focus is on Parkinson's disease and pain. We were established in 1999 as a spin-off from Pharmacia & Upjohn and are headquartered in Bresso, near Milan, Italy. We are conducting Phase III c...

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis...

Qurient Co. Ltd.

Qurient is a clinical-stage biopharmaceutical company listed in Korea Exchange (KRX 115180). Qurient has two programs in clinical development and one program in the IND enabling stage. Q301 is a topical leukotriene inhibitor for atopic dermatitis in a Phase 2b clinical trial in the United States. Q702 is a Axl/Mer/CSF1R triple inhibitor for immune-oncology...

SanBio Group

SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based investigational product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor deficit resulting from ischemic stroke, a...

GlycoGenesys, Inc.

GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product, GCS-100, a unique compound to treat cancer has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. In February 2002, the Company initiated a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clin...

Vicus Therapeutics, LLC

Vicus Therapeutics is a biopharmaceutical company dedicated to bringing breakthrough therapies to patients with cancer. Vicus' lead investigational therapy, VT-122, is a combination of etodolac and propranolol. VT-122 showed positive results in a Phase 2 clinical trial of lung cancer patients and is currently being evaluated in a Phase 2 clinical trial of liver cancer patients receiving Nexavar ...

Aurogen's technology

Aurogen's technology involves breakthrough medicine that can reduce health care costs in global markets with multibillion dollar potential and without competing comparable products. The lead product is a newly patented pharmaceutical treatment for diabetic neuropathy. Plans for product manufacture and development, including drafts of phase I/II clinical trials, have been prepared. An exciting seco...

NightstaRx Limited

Nightstar is a leading retinal gene therapy company focused on developing and commercializing novel, potentially curative one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, and for which there are no other treatment options. Nightstar’s lead program, NSR-REP1, is being developed ...

CardioVascular BioTherapeutics, Inc.

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase III trial to treat der...

EPIX Pharmaceuticals

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, ...

SanBio Co., Ltd.

SanBio (TOKYO:4592) is a leading regenerative medical products company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. The company has completed enrollment for and is conducting a Phase 2b clinical trial for its proprietary regenerative medical product SB623 for ...

Parkinson’s Institute and Clinical Center

The Parkinson’s Institute and Clinical Center is at the forefront of patient care and therapy development. We are the nation’s only Institute that provides patient care, basic science research, and clinical research in one integrated model. Our unique freestanding organization directly connects research to patient care – from the “bench to ...

Clinical Network Services (CNS)

Clinical Network Services (CNS) Pty Ltd is an Australian CRO, focused on providing full contract research organisational clinical trial services to the international healthcare community particularly during the early phase (Phase I and Phase II) clinical development of their products. CNS has established itself as Brisbane’s only headquartered Australian CRO working both nationally with dedicat...

Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in t...

Favrille

We are a biopharmaceutical company focused on the development and commercialization of patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system. We own a proprietary technology that enables us to efficiently develop and manufacture active immunotherapy products designed to stimulate a patient's own immune system to mount a specific and sustained response...

Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Bost...


More From BioPortfolio on "Cerevance Achieves Endpoints Phase Clinical Trial Novel Parkinson"

Quick Search

Corporate Database Quicklinks